This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
25I-NBOMe: Difference between revisions
>Dextromethorphan legality switzerland |
>BeavisSinatra removed 'not orally active' because people who have swallowed drugs in this category have been hospitalized. https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4355190&blobtype=pdf |
||
| Line 1: | Line 1: | ||
<br /> | |||
{{Headerpanel|{{Warning/25I-NBOMe}}}} | {{Headerpanel|{{Warning/25I-NBOMe}}}} | ||
{{SummarySheet}} | {{SummarySheet}} | ||
| Line 8: | Line 8: | ||
The name 25I-NBOMe, which short-hand for 2C-I-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-I]]. It was first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin.<ref name="Ralf Heim PhD. (2010-02-28)">Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> It was further researched by a team at Purdue University led by [[David E. Nichols|David Nichols]].<ref name="Michael Robert Braden PhD. (2007)">Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.</ref> It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).<ref>https://www.ncbi.nlm.nih.gov/pubmed/21174090</ref><ref>http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V</ref> | The name 25I-NBOMe, which short-hand for 2C-I-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-I]]. It was first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin.<ref name="Ralf Heim PhD. (2010-02-28)">Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> It was further researched by a team at Purdue University led by [[David E. Nichols|David Nichols]].<ref name="Michael Robert Braden PhD. (2007)">Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.</ref> It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).<ref>https://www.ncbi.nlm.nih.gov/pubmed/21174090</ref><ref>http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V</ref> | ||
It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] family | It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] family should be administered [[sublingual|sublingually]] by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. | ||
Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25I-NBOMe in humans. It had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}}. It has been associated with many deaths and hospitalizations. Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects. | Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25I-NBOMe in humans. It had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}}. It has been associated with many deaths and hospitalizations. Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects. | ||
| Line 23: | Line 23: | ||
The Ki values of the following targets were greater than 500 Ki: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.<ref name="high specific">High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/18468904</ref> | The Ki values of the following targets were greater than 500 Ki: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.<ref name="high specific">High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/18468904</ref> | ||
{| class="wikitable sortable" style="text-align: right; margin-left: 10px;" | {| class="wikitable sortable" style="text-align: right; margin-left: 10px;" | ||
|+ Ki-values<ref>Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/21174090</ref><ref name="high specific" /> | |+Ki-values<ref>Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/21174090</ref><ref name="high specific" /> | ||
! scope="col" | Receptor || Ki (nM) || class="unsortable" | ± | ! scope="col" |Receptor||Ki (nM)|| class="unsortable" |± | ||
|- | |- | ||
! scope="row" | [[5-HT2A|5-HT<sub>2A</sub>]] | ! scope="row" |[[5-HT2A|5-HT<sub>2A</sub>]] | ||
| 0.044 | |0.044 | ||
|- | |- | ||
! scope="row" | [[5-HT2C|5-HT<sub>2C</sub>]] | ! scope="row" |[[5-HT2C|5-HT<sub>2C</sub>]] | ||
| 2 | |2 | ||
|- | |- | ||
! scope="row" | [[5-HT6|5-HT<sub>6</sub>]] | ! scope="row" |[[5-HT6|5-HT<sub>6</sub>]] | ||
| 73 || 12 | |73||12 | ||
|- | |- | ||
! scope="row" | [[mu-opioid receptor|μ-opioid]] | ! scope="row" |[[mu-opioid receptor|μ-opioid]] | ||
| 82 || 14 | |82||14 | ||
|- | |- | ||
! scope="row" | [[Histamine H1 receptor|H<sub>1</sub>]] | ! scope="row" |[[Histamine H1 receptor|H<sub>1</sub>]] | ||
| 189 || 35 | |189||35 | ||
|- | |- | ||
! scope="row" | [[5-HT2B|5-HT<sub>2B</sub>]] | ! scope="row" |[[5-HT2B|5-HT<sub>2B</sub>]] | ||
| 231 || 73 | |231||73 | ||
|- | |- | ||
! scope="row" | [[Κ-opioid receptor|κ-opioid]] | ! scope="row" |[[Κ-opioid receptor|κ-opioid]] | ||
| 288 || 50 | |288||50 | ||
|} | |} | ||
| Line 175: | Line 175: | ||
{{#ask: [[Category:25I-NBOMe]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:25I-NBOMe]][[Category:Experience]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/exp_25INBOMe.shtml Erowid Experience Vaults: 25I-NBOMe] | |||
*[https://www.erowid.org/experiences/subs/exp_25INBOMe.shtml Erowid Experience Vaults: 25I-NBOMe] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
| Line 209: | Line 210: | ||
==Legal status== | ==Legal status== | ||
*'''Australia''': Possession, production and sale is illegal.{{citation needed}} | *'''Australia''': Possession, production and sale is illegal.{{citation needed}} | ||
*'''Austria''': Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref> | *'''Austria''': Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref> | ||
| Line 233: | Line 235: | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Research chemical]] | *[[Research chemical]] | ||
| Line 242: | Line 245: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/25I-NBOMe 25I-NBOMe (Wikipedia)] | *[https://en.wikipedia.org/wiki/25I-NBOMe 25I-NBOMe (Wikipedia)] | ||
*[https://erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml 25I-NBOMe (Erowid Vault)] | *[https://erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml 25I-NBOMe (Erowid Vault)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=5380 25I-NBOMe (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=5380 25I-NBOMe (Isomer Design)] | ||
===Discussion=== | ===Discussion=== | ||
*[http://disregardeverythingisay.com/post/49302181054/25i-nbome-broken-down-and-described 25I-NBOMe, broken down and described (Disregard Everything I Say)] | *[http://disregardeverythingisay.com/post/49302181054/25i-nbome-broken-down-and-described 25I-NBOMe, broken down and described (Disregard Everything I Say)] | ||